Clinical trials: Moxifloxacin
Anemia
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics
- Trial name
- NCT00360425
- Testing
- ferumoxytol, moxifloxacin
- Where
- United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Post Operative Endophthalmitis
Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery
This is a non-interventional, uncontrolled, prospective, multicenter, post marketing surveillance study.
- Trial name
- NCT05413980
- Testing
- Moxifloxacin hydrochloride ophthalmic solution
- Where
- 9 sites in India
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Tuberculosis, Tuberculosis Infection, Latent
Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan
RIFA-REAL is a prospective observational longitudinal study evaluating the safety, feasibility, and effectiveness of rifapentine-based shorter treatment regimens for drug-susceptible tuberculosis (DS-TB) and tuberculosis…
- Conditions
- Tuberculosis, Tuberculosis Infection, Latent, Tuberculosis, Pulmonary, Drug Sensitive
- Trial name
- RIFA-REAL (NCT07668479)
- Volunteers
- 350 people
- Sponsor
- Public Union "Kazakhstan Association of Phthisiopulmonologists"
Healthy Volunteers
Thorough QT Assessment of Cedazuridine in Healthy Subjects
This study is designed to evaluate the effect of therapeutic and supratherapeutic oral doses of cedazuridine on cardiac repolarization, as detected by QTc in healthy subjects, in accordance with regulatory guidelines.
- Trial name
- NCT04953923
- Testing
- Cedazuridine, Moxifloxacin
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Appendicitis
Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects
Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure.
- Trial name
- MAPPAC (NCT03257423)
- Testing
- Ertapenem followed by levofloxacin and metronidazole, Moxifloxacin, Appendectomy
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
Healthy
A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants
The purpose of this study is to assess the effects of aticaprant on QT/ QT interval corrected for heart rate (HR) (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic exposures in healthy…
- Trial name
- NCT05387759
- Testing
- Aticaprant Supratherapeutic Dose, Aticaprant Therapeutic Dose, Moxifloxacin
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.
- Trial name
- NCT04795479
- Testing
- Relacorilant, Moxifloxacin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
MDR-TB
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
Tuberculosis (TB) is a common, infectious, bacterial disease that is spread when an infected person transmits their saliva through the air by coughing or sneezing.
- Trial name
- STREAM (NCT02409290)
- Testing
- Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline), Moxifloxacin, Clofazimine
- Where
- 13 sites in Ethiopia, Georgia and 5 more
- Volunteers
- 588 people
- Sponsor
- IUATLD, Inc
Basic Science
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
The primary objective of the study is: To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in…
- Trial name
- NCT06411860
- Testing
- Olpasiran, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Long QT Syndrome, Hypoglycemia
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism
The human ether-a-go-go-related gene HERG (encoding Kv11.1 potassium channels) is expressed in different parts of the body including the heart, pancreas and intestines.
- Trial name
- NCT03868657
- Testing
- Moxifloxacin
- Where
- Denmark
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
COPD, Chronic Obstructive Pulmonary Disease
Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation
The purpose of this pilot study is to determine whether early treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with a combination therapy, Salmeterol + Fluticasone Propionate (SFP - Advair) will…
- Trial name
- NCT02136875
- Testing
- Double dose of Salmeterol + Fluticasone Propionate, Self-management education on the use of a self-administered prescription for exacerbation., Self-administered prescription
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COPD Exacerbation Acute
Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD
The investigators hypothesized that the empirical use of fluoroquinolones together with beta-lactam antibiotics will change their therapeutic success in patients with acute exacerbations of COPD compared to that in patients in…
- Trial name
- COPD (NCT04879030)
- Testing
- Beta-Lactams, Fluoroquinolone
- Where
- Vietnam
- Volunteers
- 170 people
- Sponsor
- Haiphong University of Medicine and Pharmacy
Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with…
- Conditions
- Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- Trial name
- NCT07170800
- Testing
- JDB0131 100mg, JDB0131 200mg, Delamanid (D)
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Cataract, Postoperative Endophthalmitis
Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery
This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.
- Trial name
- NCT07850414
- Testing
- Levofloxacin, Moxifloxacin
- Volunteers
- 93 people
- Sponsor
- Assiut University
Cataract Extraction
PRO-232 in Patients Subjected to Cataract Surgery
The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V.
- Trial name
- PRO-232 (NCT07305987)
- Testing
- Moxifloxacin / Dexamethasone Ophthalmic Solution, Moxifloxacin Hydrochloride, Ophthalmic, Dexamethasone phosphate
- Where
- 2 sites in Mexico
- Volunteers
- 134 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Systemic Lupus Erythematosus, Healthy Participants
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
- Trial name
- NCT03541564
- Testing
- BMS-986165, Moxifloxacin
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pneumonia, Acute Exacerbation of Chronic Obstructive Airways Disease
Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections
The purpose of this study is to investigate weather or not the use of a procalcitonin(PCT)-based treatment in the daily clinical work could lower the consumption of antibiotics in patients with lower respiratory tract infections.
- Trial name
- NCT02171338
- Testing
- PCT-level, Antibiotic treatment based on PCT-level
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Holbaek Sygehus
Healthy Volunteers, Cardiac Repolarisation
A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People
The trial medicine (LEO 152020) is being developed to treat people with eczema. The aims of this trial are to find out about: How the trial medicine affects participant's heart rhythm.
- Trial name
- NCT05508776
- Testing
- LEO 152020, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Triple Negative Breast Cancer
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.
- Trial name
- NCT04722978
- Testing
- Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Sun Yat-Sen University Cancer Center